Cryo-Cell International, Inc. (CCEL) Q3 Net Income Rises to $1.27M
Cryo-Cell International reported Q3 revenue of $7.82M, steady year-over-year, with net income rising to $1.27M ($0.16/share) from $749K ($0.09/share) YoY. The company showed improved earnings but no significant revenue growth, according to the company.
How this was made
The 30-second read
Why it matters
The earnings release provides the first fresh data for Q3 FY26, confirming stable revenue and improved profitability.
Market read
Micro-cap earnings with modest beat; limited trading opportunity.
What to watch
Potential upcoming regulatory changes in cell therapy could affect future growth more than this quarter's results.
Background
Cryo-Cell International is a small public company focused on cryopreserved cord blood services.
Ticker impact
Q3 FY26 earnings released showing revenue of $7.82M and net income of $1.27M, a modest beat over prior year.
likely modest upward pressure as market prices in the earnings beat
Small-cap earnings surprise with limited scale; price move expected to be limited.
Market effects
Minimal impact on the broader biotech/cryogenic services sector.
Limited to US micro-cap investors.
Low
Counterpoint
Given the tiny revenue base, the earnings beat may be inconsequential and could be priced out quickly.
Key entities
- companyCryo-Cell International, Inc.
Publicly listed provider of cryogenic storage services.
